HRP20211795T1 - Antifungalna farmaceutska formulacija - Google Patents
Antifungalna farmaceutska formulacija Download PDFInfo
- Publication number
- HRP20211795T1 HRP20211795T1 HRP20211795TT HRP20211795T HRP20211795T1 HR P20211795 T1 HRP20211795 T1 HR P20211795T1 HR P20211795T T HRP20211795T T HR P20211795TT HR P20211795 T HRP20211795 T HR P20211795T HR P20211795 T1 HRP20211795 T1 HR P20211795T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- compound
- formula
- pharmaceutically acceptable
- phenyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 20
- 230000000843 anti-fungal effect Effects 0.000 title 1
- 229940121375 antifungal agent Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 8
- 239000002245 particle Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 239000000243 solution Substances 0.000 claims 7
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 6
- SUFPWYYDCOKDLL-UHFFFAOYSA-N 2-(1,5-dimethyl-3-phenylpyrrol-2-yl)-N-[4-[4-(5-fluoropyrimidin-2-yl)piperazin-1-yl]phenyl]-2-oxoacetamide Chemical compound CN1C(=C(C=C1C)C1=CC=CC=C1)C(C(=O)NC1=CC=C(C=C1)N1CCN(CC1)C1=NC=C(C=N1)F)=O SUFPWYYDCOKDLL-UHFFFAOYSA-N 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- 238000001694 spray drying Methods 0.000 claims 4
- 229920000858 Cyclodextrin Polymers 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 229940069328 povidone Drugs 0.000 claims 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 229940125846 compound 25 Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1609222.3A GB201609222D0 (en) | 2016-05-25 | 2016-05-25 | Pharmaceutical formulation |
| EP17728590.5A EP3463365B1 (en) | 2016-05-25 | 2017-05-25 | Antifungal pharmaceutical formulation |
| PCT/GB2017/051494 WO2017203270A1 (en) | 2016-05-25 | 2017-05-25 | Pharmaceutical formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211795T1 true HRP20211795T1 (hr) | 2022-03-18 |
Family
ID=56369959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211795TT HRP20211795T1 (hr) | 2016-05-25 | 2017-05-25 | Antifungalna farmaceutska formulacija |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10973821B2 (https=) |
| EP (1) | EP3463365B1 (https=) |
| JP (1) | JP7141108B2 (https=) |
| KR (1) | KR102464150B1 (https=) |
| CN (1) | CN109982704B (https=) |
| AU (1) | AU2017270942B2 (https=) |
| CA (1) | CA3024771A1 (https=) |
| CY (1) | CY1124733T1 (https=) |
| DK (1) | DK3463365T3 (https=) |
| ES (1) | ES2888951T3 (https=) |
| GB (1) | GB201609222D0 (https=) |
| HR (1) | HRP20211795T1 (https=) |
| HU (1) | HUE056129T2 (https=) |
| IL (1) | IL263167B (https=) |
| LT (1) | LT3463365T (https=) |
| MA (1) | MA45126A (https=) |
| MX (1) | MX382199B (https=) |
| MY (1) | MY197663A (https=) |
| PL (1) | PL3463365T3 (https=) |
| PT (1) | PT3463365T (https=) |
| RU (1) | RU2760681C2 (https=) |
| SG (1) | SG11201810323RA (https=) |
| SI (1) | SI3463365T1 (https=) |
| WO (1) | WO2017203270A1 (https=) |
| ZA (1) | ZA201807851B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201609222D0 (en) * | 2016-05-25 | 2016-07-06 | F2G Ltd | Pharmaceutical formulation |
| US11819503B2 (en) | 2019-04-23 | 2023-11-21 | F2G Ltd | Method of treating coccidioides infection |
| WO2021222045A1 (en) * | 2020-04-26 | 2021-11-04 | Apollomics Inc. | Novel pharmaceutical formulation for c-met inhibitor |
| CN113429396A (zh) * | 2021-06-08 | 2021-09-24 | 深圳市祥根生物医药有限公司 | 一种五元杂芳环衍生物及其制备方法和用途 |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1051723A (https=) | 1962-04-27 | |||
| US3202654A (en) | 1962-04-27 | 1965-08-24 | Bristol Myers Co | 6-[alpha-hydroxy-and alpha-amino-alpha-pyrrolylacetamido] penicillanic acids and salts thereof |
| US3252970A (en) | 1963-02-27 | 1966-05-24 | Ciba Geigy Corp | Aromatization |
| BE631632A (https=) | 1963-04-26 | |||
| US3268558A (en) | 1964-11-05 | 1966-08-23 | Ortho Pharma Corp | 1-r-2, 4-dinitropyrroles |
| US3458515A (en) | 1966-07-21 | 1969-07-29 | American Home Prod | Piperazine substituted pyrroles |
| GB1208014A (en) | 1967-03-23 | 1970-10-07 | Glaxo Lab Ltd | Cephalosporins |
| US3573294A (en) | 1968-03-14 | 1971-03-30 | Glaxo Lab Ltd | 7 - (arylglyoxamido)cephalosporanic acids and their salts and alpha-carbonyl derivatives |
| BE790747A (fr) | 1971-10-30 | 1973-02-15 | Whitefin Holding Sa | Stereo-isomeres du 1-(1'-(0-chloro-benzyl)-pyrrol-2'-yl) -2-dibutyl sec.-amino-ethanol et procede pour leur preparation |
| GB1476503A (en) | 1973-06-21 | 1977-06-16 | Sterling Drug Inc | 1-arylamino-and 1-arylimino-pyrroles and preparation thereof |
| BE848465A (fr) | 1976-11-18 | 1977-03-16 | Stereo-isomeres de 1-(1'-benzyl-2' pyrryl)-2-disec.butylaminoethanols a activite analgesique et preparations pharmaceutiques qui les contiennent | |
| US4316900A (en) | 1977-10-05 | 1982-02-23 | Ciba-Geigy Corporation | Piperazinopyrrolobenzodiazepines |
| JPS57142966A (en) | 1981-02-27 | 1982-09-03 | Sagami Chem Res Center | (1-alkyl-2-pyrrolyl)glyoxylic acid amide derivative |
| JPS57144255A (en) | 1981-03-03 | 1982-09-06 | Sagami Chem Res Center | Alpha-methylthio(1-alkyl-2-pyrrolyl)acetamide derivative |
| US4761424A (en) | 1985-10-01 | 1988-08-02 | Warner-Lambert Company | Enolamides, pharmaceutical compositions and methods for treating inflammation |
| FR2601368B1 (fr) | 1986-07-08 | 1989-04-07 | Synthelabo | Derives de nitrofuranne, leur preparation et leur application en therapeutique. |
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| US5637592A (en) | 1994-07-12 | 1997-06-10 | Janssen Pharmaceutica N.V. | Acyl derivatives of azolones |
| JPH10505584A (ja) | 1994-07-21 | 1998-06-02 | イーライ・リリー・アンド・カンパニー | インドリジンｓＰＬＡ▲下２▼インヒビター |
| US5750540A (en) | 1995-04-28 | 1998-05-12 | Banyu Pharmaceutical Co., Ltd. | 1,4-di-substituted piperidine derivatives |
| EP0747756B1 (en) | 1995-06-06 | 2000-05-24 | Agfa-Gevaert N.V. | Photographic materials |
| JPH09249669A (ja) | 1996-03-13 | 1997-09-22 | Ono Pharmaceut Co Ltd | 縮合ピロール誘導体、およびそれらを有効成分として含有する薬剤 |
| US6133248A (en) | 1997-06-13 | 2000-10-17 | Cydex, Inc. | Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof |
| ES2287971T3 (es) | 1997-08-11 | 2007-12-16 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas con biodisponibilidad incrementada. |
| EA008723B1 (ru) | 1998-06-03 | 2007-06-29 | Джи-Пи-Ай Эн-Ай-Эл Холдингз, Инк. | Аза-гетероциклические соединения, применяемые для лечения неврологических расстройств и выпадения волос |
| US6331537B1 (en) | 1998-06-03 | 2001-12-18 | Gpi Nil Holdings, Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds |
| ATE404178T1 (de) | 1999-02-10 | 2008-08-15 | Pfizer Prod Inc | Vorrichtung mit matrixgesteuerter wirkstofffreisetzung |
| ID30409A (id) | 1999-05-04 | 2001-11-29 | Jannsen Pharmaceutica N V | Eter anti jamur |
| WO2001008572A1 (de) | 1999-07-30 | 2001-02-08 | Norbert Heske | Kanülenanordnung zum einbringen endoskopischer instrumente in einen menschlichen oder tierischen körper |
| CN1402629A (zh) | 1999-12-23 | 2003-03-12 | 辉瑞产品公司 | 提供提高的药物浓度的药物组合物 |
| GB0011089D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | Gastrin and cholecystokinin receptor ligands (11) |
| US7202239B2 (en) | 2001-04-12 | 2007-04-10 | Wyeth | Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists |
| US6825201B2 (en) | 2001-04-25 | 2004-11-30 | Bristol-Myers Squibb Company | Indole, azaindole and related heterocyclic amidopiperazine derivatives |
| JP2005501009A (ja) | 2001-06-06 | 2005-01-13 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｃａｋインヒビターおよびその使用 |
| RU2319699C2 (ru) | 2001-06-20 | 2008-03-20 | Дайити Санкио Компани, Лимитед | Производные диаминов |
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| BR0307515A (pt) | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão |
| PL372247A1 (en) | 2002-02-01 | 2005-07-11 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
| WO2003072028A2 (en) | 2002-02-23 | 2003-09-04 | Bristol-Myers Squibb Company | Method of treating hiv infection by preventing interaction of cd4 and gp120 |
| US20050255164A1 (en) | 2002-08-15 | 2005-11-17 | Yunging Liu | Solid nano pharmaceutical formulation and preparation method thereof |
| US20050032871A1 (en) | 2002-09-03 | 2005-02-10 | Sugen, Inc. | Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors |
| WO2004082606A2 (en) | 2003-03-13 | 2004-09-30 | Synta Pharmaceuticals Corp. | Fused pyrrole compounds |
| FR2854079B1 (fr) | 2003-04-25 | 2007-11-30 | Pf Medicament | Procede de preparation de complexes moleculaires |
| CL2004001884A1 (es) | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
| RU2006117635A (ru) | 2003-10-24 | 2007-12-10 | Шеринг Акциенгезельшафт (De) | Производные индолинона и их применение для лечения патологических состояний, таких как злокачественное новообразование |
| CA2568007A1 (en) | 2004-05-28 | 2005-12-08 | Pfizer Products Inc. | Pharmaceutical compositions with enhanced performance |
| US20060058286A1 (en) | 2004-09-16 | 2006-03-16 | Mark Krystal | Methods of treating HIV infection |
| WO2006082518A1 (en) | 2005-02-03 | 2006-08-10 | Pfizer Products Inc. | Pharmaceutical compositions with enhanced performance |
| JP5023054B2 (ja) | 2005-03-31 | 2012-09-12 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗バクテリア剤としての二環式ピラゾール化合物 |
| AR053713A1 (es) | 2005-04-20 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos heterociclicos y sus usos como agentes terapeuticos |
| JP5172661B2 (ja) | 2005-05-18 | 2013-03-27 | エフ２ジー リミテッド | 抗真菌剤 |
| WO2007009083A2 (en) | 2005-07-12 | 2007-01-18 | Acadia Pharmaceuticals Inc. | Compounds with activity at retinoic acid receptors |
| WO2007015866A2 (en) | 2005-07-20 | 2007-02-08 | Kalypsys, Inc. | Inhibitors of p38 kinase and methods of treating inflammatory disorders |
| WO2007109605A2 (en) | 2006-03-20 | 2007-09-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
| US8343548B2 (en) | 2006-08-08 | 2013-01-01 | Shin-Etsu Chemical Co., Ltd. | Solid dosage form comprising solid dispersion |
| US20080118500A1 (en) | 2006-11-16 | 2008-05-22 | Taiwan Liposome Company | Sustained releasing composition via local injection for treating eye diseases |
| GB0623209D0 (en) | 2006-11-21 | 2007-01-03 | F2G Ltd | Antifungal agents |
| JP5508859B2 (ja) | 2007-01-26 | 2014-06-04 | アイエスピー インヴェストメンツ インコーポレイテッド | 噴霧乾燥製品を製造するための調剤処理方法 |
| CN101260086B (zh) | 2007-03-06 | 2011-08-10 | 中国科学院上海药物研究所 | 蛋白酪氨酸磷酸酯酶1b抑制剂及其制备方法和用途 |
| GB0710121D0 (en) | 2007-05-25 | 2007-07-04 | F2G Ltd | Antifungal agents |
| US20100215747A1 (en) | 2007-07-13 | 2010-08-26 | Corey Jay Bloom | Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers |
| AU2009239778B2 (en) | 2008-04-24 | 2014-03-13 | F2G Ltd | Pyrrole antifungal agents |
| GB0809773D0 (en) | 2008-05-29 | 2008-07-09 | F2G Ltd | Antifungal combination therapy |
| US20100093872A1 (en) | 2008-10-15 | 2010-04-15 | Erimos Pharmaceuticals Llc | Stable aqueous formulations of water insoluble or poorly soluble drugs |
| CN102421435A (zh) | 2009-04-28 | 2012-04-18 | 贝林格尔.英格海姆国际有限公司 | 使用PKC-θ抑制剂的免疫性疾病的离体治疗 |
| JP5792807B2 (ja) | 2010-06-14 | 2015-10-14 | ダウ グローバル テクノロジーズ エルエルシー | アセテートおよびサクシネートの置換が向上されたヒドロキシプロピルメチルセルロースアセテートサクシネート |
| EP2611529B1 (en) | 2010-09-03 | 2019-01-23 | Bend Research, Inc. | Spray-drying method |
| EP2636409A1 (en) | 2010-11-05 | 2013-09-11 | Eisai R&D Management Co., Ltd. | Combined pharmaceutical composition as antifungal agent |
| CA2778748A1 (en) | 2011-06-01 | 2012-12-01 | Nitto Denko Corporation | Particulate preparation and method for producing the same |
| SG11201401597TA (en) | 2011-11-29 | 2014-05-29 | Jurox Pty Ltd | Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug |
| CN104427979B (zh) | 2012-04-11 | 2018-02-16 | 陶氏环球技术有限责任公司 | 具有特定的取代基分布的酯化的纤维素醚 |
| MX2015002430A (es) | 2012-08-24 | 2015-06-22 | Dow Global Technologies Llc | Acetato-succinatos de hidroxialquilmetilcelulosa. |
| KR102138546B1 (ko) | 2012-08-24 | 2020-07-28 | 다우 글로벌 테크놀로지스 엘엘씨 | 부분적으로 가교결합된 에스테르화된 셀룰로즈 에테르 |
| WO2014114575A1 (en) | 2013-01-22 | 2014-07-31 | F. Hoffmann-La Roche Ag | Pharmaceutical composition with improved bioavailability |
| HUE054186T2 (hu) | 2013-07-19 | 2021-08-30 | Boehringer Ingelheim Vetmedica Gmbh | Éterezett ciklodextrin-származékokat tartalmazó, tartósított, folyékony, vizes gyógyászati készítmény |
| WO2015007759A1 (en) | 2013-07-19 | 2015-01-22 | Boehringer Ingelheim Vetmedica Gmbh | Etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
| EP3076951B1 (en) | 2013-12-05 | 2020-09-30 | Celal Albayrak | Process for the production of drug formulations for oral administration |
| PT107568B (pt) | 2014-03-31 | 2018-11-05 | Hovione Farm S A | Processo de secagem por atomização para a produção de pós com propriedades melhoradas. |
| DK3221308T3 (en) * | 2014-11-21 | 2018-12-10 | F2G Ltd | Antifungals |
| GB201609222D0 (en) * | 2016-05-25 | 2016-07-06 | F2G Ltd | Pharmaceutical formulation |
-
2016
- 2016-05-25 GB GBGB1609222.3A patent/GB201609222D0/en not_active Ceased
-
2017
- 2017-05-25 DK DK17728590.5T patent/DK3463365T3/da active
- 2017-05-25 ES ES17728590T patent/ES2888951T3/es active Active
- 2017-05-25 EP EP17728590.5A patent/EP3463365B1/en active Active
- 2017-05-25 HR HRP20211795TT patent/HRP20211795T1/hr unknown
- 2017-05-25 WO PCT/GB2017/051494 patent/WO2017203270A1/en not_active Ceased
- 2017-05-25 RU RU2018142381A patent/RU2760681C2/ru active
- 2017-05-25 MY MYPI2018002103A patent/MY197663A/en unknown
- 2017-05-25 SG SG11201810323RA patent/SG11201810323RA/en unknown
- 2017-05-25 SI SI201730974T patent/SI3463365T1/sl unknown
- 2017-05-25 MA MA045126A patent/MA45126A/fr unknown
- 2017-05-25 CA CA3024771A patent/CA3024771A1/en active Pending
- 2017-05-25 AU AU2017270942A patent/AU2017270942B2/en active Active
- 2017-05-25 US US16/303,999 patent/US10973821B2/en active Active
- 2017-05-25 JP JP2018561686A patent/JP7141108B2/ja active Active
- 2017-05-25 IL IL263167A patent/IL263167B/en unknown
- 2017-05-25 MX MX2018014232A patent/MX382199B/es unknown
- 2017-05-25 PL PL17728590T patent/PL3463365T3/pl unknown
- 2017-05-25 PT PT177285905T patent/PT3463365T/pt unknown
- 2017-05-25 HU HUE17728590A patent/HUE056129T2/hu unknown
- 2017-05-25 LT LTEPPCT/GB2017/051494T patent/LT3463365T/lt unknown
- 2017-05-25 CN CN201780046136.8A patent/CN109982704B/zh active Active
- 2017-05-25 KR KR1020187037061A patent/KR102464150B1/ko active Active
-
2018
- 2018-11-21 ZA ZA2018/07851A patent/ZA201807851B/en unknown
-
2021
- 2021-03-01 US US17/189,091 patent/US20210186967A1/en not_active Abandoned
- 2021-11-19 CY CY20211101000T patent/CY1124733T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211795T1 (hr) | Antifungalna farmaceutska formulacija | |
| WO2022068876A1 (en) | Pharmaceutical compositions | |
| CN114306245A (zh) | 无定形固体分散体的药物组合物及其制备方法 | |
| HRP20250266T1 (hr) | Nukleotid hemi-sulfat sol za liječenje virusa hepatitisa c | |
| KR20150093819A (ko) | 약제 조성물 | |
| HRP20230210T1 (hr) | Pripravci i postupci upotrebe 2-(4-klorofenil)-n-((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-5-il)metil)-2,2-difluoroacetamida | |
| US20150064252A1 (en) | Solid dispersion formulation of an antiviral compound | |
| WO2017108605A1 (en) | Pharmaceutical composition comprising amorphous dasatinib | |
| EA021962B1 (ru) | Способ лечения шизофрении | |
| HRP20211223T1 (hr) | Heterociklički indoli za upotrebu kod infekcije virusom influence | |
| WO2013149981A1 (en) | Pharmaceutical composition with improved bioavailability, safety and tolerability | |
| JP2019516765A5 (https=) | ||
| CN101827584A (zh) | N-芳基脲基药物的固态分散体产品 | |
| Menning et al. | Fumaric acid microenvironment tablet formulation and process development for crystalline cenicriviroc mesylate, a BCS IV compound | |
| NZ748394B2 (en) | Oral and Parenteral Formulations of 2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoacetamide | |
| ES2629103T3 (es) | Formulación en polvo de valganciclovir | |
| CN101484132A (zh) | 具有合意口味的雷尼替丁制剂 | |
| JP7108681B2 (ja) | （ｒ）‐ｎ‐［１‐（３，５‐ジフルオロ‐４‐メタンスルホニルアミノ‐フェニル）‐エチル］‐３‐（２‐プロピル‐６‐トリフルオロメチル‐ピリジン‐３‐イル）‐アクリルアミドを含む医薬組成物 | |
| KR20230128040A (ko) | 비정질 고체 분산물 | |
| CN106176616B (zh) | 兽用水溶性乙氧酰胺苯甲酯纳米粉、制备方法及应用 | |
| ES2884846T3 (es) | Agente terapéutico para la disfunción del lóbulo frontal | |
| AU2023202089B2 (en) | Pemetrexed formulations | |
| JP5984923B2 (ja) | 速溶性アザペロン顆粒製剤 | |
| JPWO2017170460A1 (ja) | 炎症性腸疾患治療剤 | |
| WO2025139681A1 (zh) | 眼用药物组合物及其用途 |